Pembrolizumab-Induced Primary Adrenal Insufficiency: A Rare But Life-Threatening Endocrine irAE
Pembrolizumab, a PD-1 checkpoint inhibitor, is widely used in the treatment of various malignancies. While it improves overall survival, it can lead to immune-related adverse events (irAEs), including rare endocrine disorders such as primary adrenal insufficiency (PAI). We present a case of PAI induced by Pembrolizumab in a 75-year-old man, emphasizing the importance of early recognition and timely management.
Authors
- Syeda Sarah Raza
- Abdullah A Orakzai
- Mehr A Orakzai
Publication Details
- Journal
- Advances in Clinical Medical Research and Healthcare Delivery
- Published
- 2026-02-01
- DOI
- https://doi.org/10.53785/2769-2779.1341
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00